Section Arrow
ARDX.NASDAQ
- Ardelyx
Quotes are at least 15-min delayed:2025/07/15 23:47 EDT
Regular Hours
Last
 4.5
-0.11 (-2.39%)
Day High 
4.6699 
Prev. Close
4.61 
1-M High
4.715 
Volume 
3.04M 
Bid
4.46
Ask
4.51
Day Low
4.49 
Open
4.63 
1-M Low
3.49 
Market Cap 
1.10B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.35 
20-SMA 3.99 
50-SMA 3.9 
52-W High 7.18 
52-W Low 3.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.23/-0.19
Enterprise Value
1.25B
Balance Sheet
Book Value Per Share
0.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
333.62M
Operating Revenue Per Share
0.56
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
NCNANuCana plc0.0502+0.0043+9.37%-- 
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
Quotes are at least 15-min delayed:2025/07/15 23:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adultswith IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.